John Patrick Shannon Jr Xeris Biopharma Holdings, Inc. (XERS) insider trading activity

John Patrick Shannon Jr is Director of Xeris Biopharma Holdings, Inc.. Currently has a direct ownership of 2.71 Million shares of XERS, which is worth approximately $19.6 Million. The most recent transaction as insider was on Jan 05, 2026, when has been sold 24,907 shares (Common Stock) at a price of $7.08 per share, resulting in proceeds of $176,341. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 2.71M

1.8% 3M change

28.3% 12M change

Total Value Held $19.6 Million

John Patrick Shannon Jr Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 05 2026	SELL Open market or private sale	$176,341 $7.08 p/Share	24,907 Reduced 0.91%	2,705,346 Common Stock
Jan 05 2026	BUY Exercise of conversion of derivative security	$216,907 $2.35 p/Share	92,301 Added 3.19%	2,797,647 Common Stock
Nov 14 2025	BUY Exercise of conversion of derivative security	$135,005 $1.55 p/Share	87,100 Added 3.09%	2,730,253 Common Stock
Nov 13 2025	SELL Open market or private sale	$173,385 $7.46 p/Share	23,242 Reduced 0.87%	2,643,153 Common Stock
Nov 13 2025	BUY Exercise of conversion of derivative security	$13,903 $1.55 p/Share	8,970 Added 0.34%	2,666,395 Common Stock
Aug 01 2025	SELL Payment of exercise price or tax liability	$198,618 $5.38 p/Share	36,918 Reduced 1.37%	2,657,425 Common Stock
Jan 31 2025	SELL Payment of exercise price or tax liability	$788,540 $3.56 p/Share	221,500 Reduced 10.5%	1,887,118 Common Stock

Jan 31 2025	BUY Grant, award, or other acquisition	-	800,000 Added 22.94%	2,687,118 Common Stock
Jan 03 2025	SELL Payment of exercise price or tax liability	$142,389 $3.61 p/Share	39,443 Reduced 1.84%	2,108,618 Common Stock
Aug 01 2024	BUY Grant, award, or other acquisition	-	250,000 Added 9.36%	2,419,612 Common Stock
Jan 31 2024	SELL Payment of exercise price or tax liability	$272,445 $2.46 p/Share	110,750 Reduced 4.9%	2,148,061 Common Stock
Jan 31 2024	BUY Grant, award, or other acquisition	-	750,000 Added 25.79%	2,158,575 Common Stock
Jan 29 2024	SELL Payment of exercise price or tax liability	$58,919 $2.66 p/Share	22,150 Reduced 0.97%	2,258,811 Common Stock
Jan 03 2024	SELL Payment of exercise price or tax liability	$91,468 $2.24 p/Share	40,834 Reduced 1.76%	2,280,961 Common Stock
Nov 17 2023	BUY Open market or private purchase	$50,461 $1.64 p/Share	30,769 Added 2.14%	1,408,575 Common Stock
Jan 31 2023	SELL Payment of exercise price or tax liability	$12,251 $1.24 p/Share	9,880 Reduced 0.42%	2,321,795 Common Stock
Jan 31 2023	BUY Grant, award, or other acquisition	-	750,000 Added 35.25%	1,377,806 Common Stock
Jan 29 2023	SELL Payment of exercise price or tax liability	$29,501 $1.26 p/Share	23,414 Reduced 0.99%	2,331,675 Common Stock
Jan 03 2023	SELL Payment of exercise price or tax liability	$46,294 $1.12 p/Share	41,334 Reduced 1.72%	2,355,089 Common Stock
Jan 31 2022	SELL Payment of exercise price or tax liability	$15,818 $2.11 p/Share	7,497 Reduced 0.31%	2,396,423 Common Stock
Jan 29 2022	SELL Payment of exercise price or tax liability	$33,110 $2.11 p/Share	15,692 Reduced 0.65%	2,403,920 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	250,000 Added 28.77%	618,910 Common Stock
Nov 12 2021	BUY Open market or private purchase	$126,000 $2.1 p/Share	60,000 Added 14.16%	363,829 Common Stock
Nov 11 2021	BUY Open market or private purchase	$83,600 $2.09 p/Share	40,000 Added 11.63%	303,829 Common Stock
Oct 05 2021	BUY Grant, award, or other acquisition	-	263,829 Added 50.0%	263,829 Common Stock

Also insider at

XERS

XERIS PHARMACEUTICALS INC Healthcare

Officer

JPS